STMicroelectronics stock rises on decade-long SpaceX partnership

Investing.com -- Amphastar Pharmaceuticals (NASDAQ:AMPH) stock gained 2.3% in Monday’s premarket trading after the company announced FDA approval of its teriparatide injection, a generic equivalent to Eli Lilly’s (NYSE:LLY) FORTEO.

The approval marks Amphastar’s first pen device combination product, which is indicated for treating osteoporosis in various patient populations. According to IQVIA data, the overall U.S. market for teriparatide injection reached approximately $585 million for the 12 months ended September 30, 2025.

Amphastar plans to launch the product by the end of the year, with the drug manufactured at its U.S. facility. This domestic production capability provides a potential advantage in the market where many competitors rely on overseas manufacturing.

"We are proud to announce FDA approval of Amphastar’s first-ever pen device combination product, demonstrating our continued commitment to advancing innovative approaches for complex drug delivery mechanisms," said Dr. Jack Zhang, Amphastar’s President and CEO.

The company’s pipeline includes two ANDAs and one biosimilar insulin filed with the FDA targeting products with a combined market size exceeding $1.8 billion. Additionally, Amphastar is developing three biosimilar products targeting a market exceeding $6 billion and two generic products targeting a market of over $1 billion.

Amphastar has also entered into an exclusive license agreement with Anji for the development of three proprietary peptides targeting cancer treatment and wet age-related macular degeneration.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Berenberg has upgraded Neste Oyj (HE:NESTE) to Buy, raising its price target to €26 from €16.50, as the broker moves to reflect what it sees as a faster-than-expected recovery and more attractive long-term fundamentals.

The new target implies around 40% upside from current levels. The stock has more than doubled from its April lows, though it remains around 60% lower over a three-year view, Berenberg analysts led by Henry Tarr said.

The analysts say earlier concerns around oversupply in renewable fuels weighing on margins through 2025 and 2026 are easing as demand conditions improve and operational performance strengthens.

While acknowledging that near-term margins could still be volatile, the team now expects renewable sales volumes to grow at a 12% compound annual rate over the next three years, with sales margins recovering to about $575 per ton.

That underpins an estimated 25% EBITDA compound annual growth rate (CAGR) and leaves the shares trading on 5.8 times 2028 enterprise value to EBITDA.

Demand visibility has improved across key markets. In Europe, the impact of the EU’s Renewable Energy Directive III is starting to be felt, with Germany recently passing draft legislation that should support significantly higher renewable fuel volumes from 2026.

“The 2026 renewable volume obligation in the U.S. is also expected to be sharply higher, which should support margins in the country next year,” the analysts said.

The broker also highlights company-specific factors. Neste’s new management team is focused on improving operational efficiency and lowering costs, while capital expenditure is expected to trend lower, allowing the balance sheet to steadily improve.

The company has scope to ramp up production into a strengthening market, with renewable sales expected at around 4.1 million tons in 2025 versus headline capacity rising to roughly 6.8 million tons by 2027 as the Rotterdam facility starts up.

Several risks remain, including weaker diesel prices, soft refining margins and significant planned maintenance in the fourth quarter.

Still, analysts believe any near-term weakness should be viewed as an opportunity, given what they describe as clear growth potential over the next three years.

Investing.com -- ReNew Energy Global (NASDAQ:RNW) stock fell 24% after Masdar confirmed its withdrawal from the consortium pursuing a potential buyout of the company.

According to a statement released on December 14, 2025, Masdar informed other consortium members that it has pulled out of the group, effectively ending the proposed transaction. The consortium had previously included Masdar, Canada Pension Plan Investment Board, Abu Dhabi Investment Authority, and ReNew founder Sumant Sinha.

The abandoned deal marks a significant setback for ReNew shareholders, who had seen a potential exit opportunity when the consortium announced an agreement in principle on October 28 for a cash buyout offer of $8.15 per share.

The company has not yet announced any alternative strategic plans following the collapse of the proposed transaction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.